Abstract
This year is the 50th anniversary of the introduction into clinical use of the first modern inhaler for the management of asthma — the pressurised metered-dose inhaler (pMDI). The pMDI was initially used for the administration of the non-selective beta-agonists adrenaline and isoprenaline. However, the epidemic of asthma deaths which occurred in the 1960s led to these drugs being superseded by the selective short-acting beta-agonist salbutamol, and the first inhaled corticosteroid (ICS) beclomethasone. At the same time, sodium cromoglycate was introduced, to be administered via the first dry-powder inhaler — the Spinhaler — but owing to its relatively weak anti-inflammatory action its use is now very limited. Over the last 10 years, the long-acting beta-agonists (LABAs) have become an important add-on therapy for the management of asthma, and they are now often used with ICS in a single ICS/LABA combination inhaler.
You have full access to this article via your institution.
Similar content being viewed by others
Article PDF
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Crompton, G. A brief history of inhaled asthma therapy over the last fifty years. Prim Care Respir J 15, 326–331 (2006). https://doi.org/10.1016/j.pcrj.2006.09.002
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1016/j.pcrj.2006.09.002
This article is cited by
-
The Changing Asthma Management Landscape and Need for Appropriate SABA Prescription
Advances in Therapy (2023)
-
Safety of SABA Monotherapy in Asthma Management: a Systematic Review and Meta-analysis
Advances in Therapy (2023)
-
How we teach children with asthma to use their inhaler: a scoping review
Italian Journal of Pediatrics (2022)
-
Comparison of the knowledge and skill levels of pharmacists and pharmacy technicians on the implementation of inhaler drug-delivery devices: a cross-sectional study in Şanlıurfa, Turkey
Drugs & Therapy Perspectives (2022)
-
Expert Opinion on Practice Patterns in Mild Asthma After the GINA 2019 Updates: A Major Shift in Treatment Paradigms from a Long-Standing SABA-Only Approach to a Risk Reduction–Based Strategy with the Use of Symptom-Driven (As-Needed) Low-Dose ICS/LABA
Current Allergy and Asthma Reports (2022)